REGENXBIO (RGNX) Sees IPO Price of $17 - $19/Share

REGENXBIO Inc. (Nasdaq: RGNX) filed an amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to offer 5,555,555 common shares and sees pricing of $17 - $19 per share. The company plans to list on the NYSE under the ticker "RGNX."

Underwriters on the offering are Morgan Stanley, BofA/Merrill Lynch, Piper Jaffray & Co., and Chardan Capital Markets.

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.

You May Also Be Interested In

• SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
• Elroy Air wins $46M U.S. Army contract for cargo drone system
• Jupiter Neurosciences prices $2M registered direct offering of shares